PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1

PepGen Inc. (NASDAQ:PEPG) will cease DMD research due to failed trial results, focusing on DM1 program instead. CEO James McArthur expressed disappointment but highlighted promising prospects in DM1 therapy.